Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEE011 plus Cetuximab in Head and Neck Cancer
NCT02429089Phase 1Terminated
- Start
- Apr 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in squamous cell carcinoma of the head and neck (HNSCC). Primary endpoint: Maximum Tolerated Dose up to 20 months. Started Apr 2015; status: terminated.
02
Drugs
ribociclib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02429089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429089.